Table 4. Geometric means of pharmacokinetic parameters (C_max, C_τ, and AUC_0–τ) by BMI (≥median versus <median).

Injection	Parameter	Cohort 1			Cohort 2
		≥Median BMI*	<Median BMI*	p-Value	≥Median BMI*	<Median BMI*	p-Value
1	n	41	33		26	33
	Cmax (μg/ml)	1.82	2.56	0.014	1.35	2.37	<0.001
	Cτ (μg/ml)	0.73	0.81	0.454	1.12	1.82	0.001
	AUC0–τ (d*μg/ml)	99.09	130.12	0.010	27.47	48.24	<0.001
2	n	36	26		26	33
	Cmax (μg/ml)	2.14	2.78	0.086	2.82	3.63	0.075
	Cτ (μg/ml)	1.10	1.09	0.946	1.40	1.82	0.085
	AUC0–τ (d*μg/ml)	132.21	165.50	0.051	111.83	150.36	0.025
3	n	33	24		24	33
	Cmax (μg/ml)	2.93	3.48	0.272	2.57	3.90	0.005
	Cτ (μg/ml)	1.17	1.39	0.289	1.53	1.74	0.394
	AUC0–τ (d*μg/ml)	181.07	225.81	0.065	113.68	171.86	0.002
4	n				24	31
	Cmax (μg/ml)				2.69	3.65	0.040
	Cτ (μg/ml)				1.85	1.81	0.887
	AUC0–τ (d*μg/ml)				123.14	152.50	0.116
5	n				24	26
	Cmax (μg/ml)				3.27	4.18	0.112
	Cτ (μg/ml)				1.92	1.87	0.881
	AUC0–τ (d*μg/ml)				153.49	178.63	0.284

Includes plasma cabotegravir concentrations obtained from samples collected within defined post-injection sampling windows.

*Median BMI is 27.2 kg/m² for females and 25.0 kg/m² for males. AUC_0–τ, area under the plasma concentration–time curve over the dosing interval; BMI, body mass index; C_max, maximum plasma concentration; C_τ, trough concentration at the end of the dosing interval.